Free Trial

Windtree Therapeutics (WINT) Competitors

Windtree Therapeutics logo
$0.60 0.00 (-0.50%)
Closing price 06/17/2025 04:00 PM Eastern
Extended Trading
$0.57 -0.03 (-4.86%)
As of 04:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

WINT vs. ACXP, SLXN, HCWB, CHRO, PRTG, OBSV, GTBP, CVM, APLM, and SBFM

Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Acurx Pharmaceuticals (ACXP), Silexion Therapeutics (SLXN), HCW Biologics (HCWB), Chromocell Therapeutics (CHRO), Portage Biotech (PRTG), ObsEva (OBSV), GT Biopharma (GTBP), CEL-SCI (CVM), Apollomics (APLM), and Sunshine Biopharma (SBFM). These companies are all part of the "pharmaceutical products" industry.

Windtree Therapeutics vs. Its Competitors

Windtree Therapeutics (NASDAQ:WINT) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Acurx Pharmaceuticals received 14 more outperform votes than Windtree Therapeutics when rated by MarketBeat users. Likewise, 94.44% of users gave Acurx Pharmaceuticals an outperform vote while only 37.50% of users gave Windtree Therapeutics an outperform vote.

CompanyUnderperformOutperform
Windtree TherapeuticsOutperform Votes
3
37.50%
Underperform Votes
5
62.50%
Acurx PharmaceuticalsOutperform Votes
17
94.44%
Underperform Votes
1
5.56%

In the previous week, Windtree Therapeutics and Windtree Therapeutics both had 6 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 1.87 beat Windtree Therapeutics' score of 0.62 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Windtree Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Acurx Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Windtree Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.38, indicating that its stock price is 238% less volatile than the S&P 500.

Windtree Therapeutics presently has a consensus price target of $350.00, suggesting a potential upside of 58,526.47%. Acurx Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 874.78%. Given Windtree Therapeutics' higher probable upside, analysts plainly believe Windtree Therapeutics is more favorable than Acurx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Acurx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Windtree Therapeutics' return on equity of -227.93% beat Acurx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -227.93% -56.46%
Acurx Pharmaceuticals N/A -526.78%-223.78%

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$823.470.00
Acurx PharmaceuticalsN/AN/A-$14.10M-$0.70-1.17

29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 0.3% of Windtree Therapeutics shares are owned by insiders. Comparatively, 26.0% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Windtree Therapeutics and Acurx Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Windtree Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WINT vs. The Competition

MetricWindtree TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.17M$3.19B$5.33B$8.57B
Dividend YieldN/A2.59%5.32%4.20%
P/E Ratio0.0023.7425.9319.01
Price / SalesN/A305.97419.05111.92
Price / CashN/A36.2535.6355.74
Price / Book0.027.827.815.05
Net Income-$1.79M-$52.71M$3.15B$249.31M
7 Day Performance-14.69%-3.75%-2.65%-1.87%
1 Month Performance-27.90%8.84%4.37%2.24%
1 Year Performance-99.65%0.47%35.72%15.05%

Windtree Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WINT
Windtree Therapeutics
1.6906 of 5 stars
$0.60
-0.5%
$350.00
+58,526.5%
-99.6%$2.17MN/A0.0030News Coverage
Short Interest ↑
Gap Down
ACXP
Acurx Pharmaceuticals
3.2734 of 5 stars
$0.33
-3.5%
$8.00
+2,288.8%
-65.5%$8.15MN/A-0.313News Coverage
Options Volume
Gap Up
SLXN
Silexion Therapeutics
N/A$0.93
-1.2%
$5.00
+435.2%
N/A$8.12MN/A0.00N/A
HCWB
HCW Biologics
3.2756 of 5 stars
$5.58
-7.6%
$35.00
+527.2%
-87.0%$8.03M$1.45M-5.5840Gap Down
CHRO
Chromocell Therapeutics
1.0068 of 5 stars
$1.21
+6.2%
N/A-1.0%$7.98MN/A-0.984News Coverage
Short Interest ↓
Gap Up
PRTG
Portage Biotech
0.4859 of 5 stars
$7.60
-9.6%
N/A+19.6%$7.97MN/A-0.186
OBSV
ObsEva
N/AN/AN/AN/A$7.94M$20.11M-0.1150
GTBP
GT Biopharma
2.0592 of 5 stars
$3.02
+12.7%
$11.00
+264.2%
-4.1%$7.81MN/A-0.538Gap Up
CVM
CEL-SCI
0.1005 of 5 stars
$2.54
+6.7%
N/A-93.8%$7.70MN/A-5.2943High Trading Volume
APLM
Apollomics
0.7344 of 5 stars
$6.75
+3.8%
N/A-66.6%$7.45M$1.22M0.0045Positive News
SBFM
Sunshine Biopharma
2.876 of 5 stars
$1.57
+4.0%
$15.00
+855.4%
+384.8%$7.15M$36.23M-0.013

Related Companies and Tools


This page (NASDAQ:WINT) was last updated on 6/18/2025 by MarketBeat.com Staff
From Our Partners